Canaccord Genuity Reiterates a 'Buy' on Edwards Lifesciences (EW); Positive Final NCD

May 2, 2012 10:26 AM EDT
Get Alerts EW Hot Sheet
Price: $89.79 -0.04%

Rating Summary:
    31 Buy, 14 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 8 | Down: 5 | New: 26
Join SI Premium – FREE
Canaccord Genuity reiterates a 'Buy' on Edwards Lifesciences (NYSE: EW) price target of $93.00.

Analyst, Jason R. Mills, said, "We think Medicare’s final NCD on TAVI is positive, as it allows for coverage of evidence development and coverage of non-inferiority trials. We recommend investors overweight EW relative to the mid/large-cap med-tech peer group owing to EW’s auspicious top-line growth prospects and exciting potential for significant operating leverage via TAVI uptake in the years to come...We remain comfortable with our recently-increased US SAPIEN revenue estimates for 2012 and 2013 of $208M (+500%) and $330M (+59%), respectively."

For an analyst ratings summary and ratings history on Edwards Lifesciences click here. For more ratings news on Edwards Lifesciences click here.

Shares of Edwards Lifesciences closed at $84.78 yesterday.


Serious News for Serious Traders! Try StreetInsider.com Premium Free!

You May Also Be Interested In





Related Categories

Analyst Comments